Shares of ImmuPharma plc (LON:IMM – Get Free Report) fell 7.3% during trading on Friday . The stock traded as low as GBX 1.07 ($0.01) and last traded at GBX 1.15 ($0.01). 269,778 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 1,793,761 shares. The stock had previously closed at GBX 1.24 ($0.02).
ImmuPharma Price Performance
The firm has a market capitalization of £5.08 million, a PE ratio of -122.00 and a beta of 1.53. The firm’s fifty day moving average is GBX 1.45 and its two-hundred day moving average is GBX 1.70.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More
- Five stocks we like better than ImmuPharma
- What is a Death Cross in Stocks?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- What is the Shanghai Stock Exchange Composite Index?
- Top 3 ETFs to Hedge Against Inflation in 2025
- When to Sell a Stock for Profit or Loss
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
